Literature DB >> 21843301

Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes.

A G Jones1, R E J Besser, T J McDonald, B M Shields, S V Hope, P Bowman, R A Oram, B A Knight, A T Hattersley.   

Abstract

AIMS: Serum C-peptide measurement can assist clinical management of diabetes, but practicalities of collection limit widespread use. Urine C-peptide creatinine ratio may be a non-invasive practical alternative. The stability of C-peptide in urine allows outpatient or community testing. We aimed to assess how urine C-peptide creatinine ratio compared with serum C-peptide measurement during a mixed-meal tolerance test in individuals with late-onset, insulin-treated diabetes.
METHODS: We correlated the gold standard of a stimulated serum C-peptide in a mixed-meal tolerance test with fasting and stimulated (mixed-meal tolerance test, standard home meal and largest home meal) urine C-peptide creatinine ratio in 51 subjects with insulin-treated diabetes (diagnosis after age 30 years, median age 66 years, median age at diagnosis 54, 42 with Type 2 diabetes, estimated glomerular filtration rate > 60 ml min(-1) 1.73 m(-2) ).
RESULTS: Ninety-minute mixed-meal tolerance test serum C-peptide is correlated with mixed-meal tolerance test-stimulated urine C-peptide creatinine ratio (r = 0.82), urine C-peptide creatinine ratio after a standard breakfast at home (r = 0.73) and urine C-peptide creatinine ratio after largest home meal (r = 0.71). A stimulated (largest home meal) urine C-peptide creatinine ratio cut-off of 0.3 nmol/mmol had a 100% sensitivity and 96% specificity (area under receiver operating characteristic curve = 0.99) in identifying subjects without clinically significant endogenous insulin secretion (mixed-meal tolerance test-stimulated C-peptide < 0.2 nmol/l). In detecting a proposed serum C-peptide threshold for insulin requirement (stimulated serum C-peptide < 0.6 nmol/l), a stimulated (largest home meal) urine C-peptide creatinine ratio cut-off of 0.6 nmol/mmol had a sensitivity and specificity of 92%.
CONCLUSION: In patients with insulin-treated diabetes diagnosed after age 30 years, urine C-peptide creatinine ratio is well correlated with serum C-peptide and may provide a practical alternative measure to detect insulin deficiency for use in routine clinical practice.
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21843301     DOI: 10.1111/j.1464-5491.2011.03272.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  15 in total

1.  Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic.

Authors:  S V Hope; B A Knight; B M Shields; A T Hattersley; T J McDonald; A G Jones
Journal:  Diabet Med       Date:  2016-05-26       Impact factor: 4.359

2.  Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors.

Authors:  Richard A Oram; Timothy J McDonald; Beverley M Shields; Michelle M Hudson; Maggie H Shepherd; Suzanne Hammersley; Ewan R Pearson; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2014-12-17       Impact factor: 19.112

3.  Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin.

Authors:  Angus G Jones; Rachel Ej Besser; Beverley M Shields; Timothy J McDonald; Suzy V Hope; Bridget A Knight; Andrew T Hattersley
Journal:  BMC Endocr Disord       Date:  2012-06-08       Impact factor: 2.763

Review 4.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

5.  Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study.

Authors:  Richard A Oram; Andrew Rawlingson; Beverley M Shields; Coralie Bingham; Rachel E J Besser; Tim J McDonald; Bridget A Knight; Andrew T Hattersley
Journal:  BMJ Open       Date:  2013-12-18       Impact factor: 2.692

6.  The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells.

Authors:  Richard A Oram; Angus G Jones; Rachel E J Besser; Bridget A Knight; Beverley M Shields; Richard J Brown; Andrew T Hattersley; Timothy J McDonald
Journal:  Diabetologia       Date:  2014-01       Impact factor: 10.122

7.  Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.

Authors:  John M Dennis; Beverley M Shields; Anita V Hill; Bridget A Knight; Timothy J McDonald; Lauren R Rodgers; Michael N Weedon; William E Henley; Naveed Sattar; Rury R Holman; Ewan R Pearson; Andrew T Hattersley; Angus G Jones
Journal:  Diabetes Care       Date:  2018-01-31       Impact factor: 19.112

8.  Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.

Authors:  Angus G Jones; Timothy J McDonald; Beverley M Shields; Anita V Hill; Christopher J Hyde; Bridget A Knight; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2015-08-04       Impact factor: 19.112

9.  Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients.

Authors:  Hye-Jin Yoon; Youn-Zoo Cho; Ji-Young Kim; Byung-Joon Kim; Keun-Young Park; Gwan-Pyo Koh; Dae-Ho Lee; Dong-Mee Lim
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

10.  A new strategy for early diagnosis of type 2 diabetes by standard-free, label-free LC-MS/MS quantification of glycated peptides.

Authors:  Mei Zhang; Wei Xu; Yulin Deng
Journal:  Diabetes       Date:  2013-07-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.